RVMDRevolution Medicines, Inc. Common Stock

CSNasdaq (XNAS)·USD

Identity

Security key: 21193
Ticker: RVMD
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2020-02-13
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: RVMD

Detail

Enriched 2026-08-14 20:47

Market cap: $43,994,693,158.68
Shares outstanding (class): 214,336,418
Shares outstanding (weighted): 214,336,418
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees: 883
Location: REDWOOD CITY, CA
Homepage: https://www.revmed.com
Description: Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.

Market cap and share counts drift.

Funds holding this security

225 funds · 234 positions · $2.89B reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$581.82M	0.03%	5,982,719 NS	FIGI
VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS	VB	$422.17M	0.26%	4,341,039 NS	FIGI
VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS	VBK	$236.18M	0.61%	2,428,562 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$197.29M	0.24%	2,028,710 NS	FIGI
T. Rowe Price Health Sciences Fund, Inc. T. ROWE PRICE HEALTH SCIENCES FUND, INC.	—	$147.79M	1.36%	1,519,722 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$124.86M	1.54%	1,283,912 NS	FIGI
Janus Henderson Global Life Sciences Fund JANUS INVESTMENT FUND	—	$105.81M	2.04%	1,088,018 NS	FIGI
Janus Henderson Enterprise Fund JANUS INVESTMENT FUND	—	$97.22M	0.48%	999,703 NS	FIGI
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$82.74M	1.11%	850,768 NS	FIGI
iShares Russell Mid-Cap ETF iShares Trust	IWR	$63.09M	0.13%	648,760 NS	FIGI
Janus Henderson Triton Fund JANUS INVESTMENT FUND	—	$53.94M	1.04%	554,682 NS	FIGI
Janus Henderson Research Fund JANUS INVESTMENT FUND	—	$48.85M	0.20%	502,273 NS	FIGI
iShares Russell 1000 Value ETF iShares Trust	IWD	$37.95M	0.05%	390,206 NS	FIGI
Janus Henderson Venture Fund JANUS INVESTMENT FUND	—	$36.09M	1.18%	371,147 NS	FIGI
T. Rowe Price New Horizons Fund, Inc. T. ROWE PRICE NEW HORIZONS FUND, INC.	—	$32.04M	0.25%	329,504 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERRVMD
FIGI_COMPOSITEBBG00829F4P8
FIGI_SHARE_CLASSBBG00829F4Q7
CIK0001628171
ISINUS76155X1000
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Revolution Medicines is a clinical-stage biopharmaceutical company developing targeted therapies for cancer, fitting the biotechnology industry.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.